ArticleBMJ open diabetes research & care2021
Plasma N-glycome shows continuous deterioration as the diagnosis of insulin resistance approaches.
Article in BMJ open diabetes research & care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Large glycomics datasets as a tool to understand the function of glycans.Nature chemical biology · 2026Review
- Machine Learning-Based Identification of Serum Metabolic Signatures in Adult Patients with Type 1 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Longitudinal study reveals plasma glycans associations with prediabetes/type 2 diabetes in KORA study.Cardiovascular diabetology · 2025Article
- IgG N-glycosylation contributes to different severities of insulin resistance: implications for 3P medical approaches.The EPMA journal · 2025Article
- Plasma N-Glycoproteomics in monozygotic twin pairs discordant for body mass index reveals an obesity signature related to inflammation and iron metabolism.Biology direct · 2025Article
- Cognitive decline in older adults with type 2 diabetes: Unraveling site-specific glycoproteomic alterations.PloS one · 2025Article
- Glycosylation: mechanisms, biological functions and clinical implications.Signal transduction and targeted therapy · 2024Review
- Predicting glycan structure from tandem mass spectrometry via deep learning.Nature methods · 2024Article
- Plasma protein N-glycome composition associates with postprandial lipaemic response.BMC medicine · 2023Review
- Not-So-Sweet Dreams: Plasma and IgG N-Glycome in the Severe Form of the Obstructive Sleep Apnea.Biomolecules · 2023Article
- TheBiomolecules · 2023Article
- Susceptibility of Human Plasma N-glycome to Low-Calorie and Different Weight-Maintenance Diets.International journal of molecular sciences · 2022Article
- Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.Diabetes care · 2022Article
- High-Throughput Glycomic Methods.Chemical reviews · 2022Review
- Multi-block data integration analysis for identifying and validating targeted N-glycans as biomarkers for type II diabetes mellitus.Scientific reports · 2022Article
- Comparison of self-sampling blood collection for N-glycosylation analysis.BMC research notes · 2022Article
- In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.Frontiers in chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 4 countries.
Funding
Abstract
introductionPrediction of type 2 diabetes mellitus (T2DM) and its preceding factors, such as insulin resistance (IR), is of great importance as it may allow delay or prevention of onset of the disease. Plasma protein N-glycome has emerged as a promising predictive biomarker. In a prospective longitudinal study, we included patients with a first diagnosis of impaired glucose metabolism (IR or T2DM) to investigate the N-glycosylation's predictive value years before diabetes development. RESEARCH DESIGN AND
methodsPlasma protein N-glycome was profiled by hydrophilic interaction ultra-performance liquid chromatography in 534 TwinsUK participants free from disease at baseline. This included 89 participants with incident diagnosis of IR or T2DM during the follow-up period (7.14±3.04 years) whose last sample prior to diagnosis was compared using general linear regression with 445 age-matched unrelated controls. Findings were replicated in an independent cohort. Changes in N-glycome have also been presented in connection with time to diagnosis.
resultsEight groups of plasma N-glycans were different between incident IR or T2DM cases and controls (p<0.05) after adjusting for multiple testing using Benjamini-Hochberg correction. These differences were noticeable up to 10 years prior to diagnosis and are changing continuously as becoming more expressed toward the diagnosis. The prediction model was built using significant glycan traits, displaying a discriminative performance with an area under the receiver operating characteristic curve of 0.77.
conclusionsIn addition to previous studies, we showed the diagnostic potential of plasma N-glycome in the prediction of both IR and T2DM development years before the clinical manifestation and indicated the continuous deterioration of N-glycome toward the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.